AMENDMENT NO. 1 - DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • May 8th, 2014 • Zogenix, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 – DEVELOPMENT AND OPTION AGREEMENT (the “Amendment No. 1”) is made as of March 10th, 2014 (the “Amendment No. 1 Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
TERMINATION AND AMENDMENT AGREEMENTTermination and Amendment Agreement • May 8th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
This Termination and Amendment Agreement (this “Agreement”) is made as of January 8, 2014 (the “Agreement Date”), to be effective as of January 31, 2014 (the “Termination Effective Date”), by and between Zogenix, Inc., a Delaware corporation (“Zogenix”), and Mallinckrodt LLC, a Delaware limited liability company (“Mallinckrodt”). Each of Zogenix and Mallinckrodt is referred to herein, individually, as a “Party” and, collectively, as the “Parties.” Defined terms used in this Agreement, without definition set forth herein, shall have the meanings given them in the Co-Promotion Agreement (as defined below).
